Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bertilimumab - Immune Pharmaceuticals

Drug Profile

Bertilimumab - Immune Pharmaceuticals

Alternative Names: Anti-eotaxin human monoclonal antibody; CAT-213; iCo-008

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Cambridge Antibody Technology; iCo Therapeutics; Immune Pharmaceuticals Inc
  • Class Antiallergics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bullous pemphigoid
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bullous pemphigoid; Crohn's disease; Ulcerative colitis
  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Allergic conjunctivitis; Asthma; Atopic dermatitis; Wet age-related macular degeneration
  • Discontinued Allergic rhinitis; Ovarian cancer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Atopic-dermatitis in Israel
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (Parenteral)
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in Canada (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top